Devon Labs is an innovative company created with the objective of improving the quality of life of patients and their carers, through commercializing our own portfolio of products. We focus on niche markets with the aim of resolving unmet needs and developing a new focus supported by digital technologies that complement conventional treatment.
Devon Labs originated from Devon Farmacéutica, a Spanish company created in 2003.
Continuous growth for more than 15 years in Spain and other parts of Europe.
ProStrakan is acquired by Kyowa Hakko Kirin, a Japanese company with a global presence.
In October 2020 an agreement was signed with Sandoz (Group Novartis) for the launch of four products in the areas of Oncology and Pain.
A team that has worked together for more than ten years, with a proven track record of setting up companies and business units, as well as launching products in diverse therapeutic areas.
Gabriel, CEO and Founder of Devon Labs, has 30 years experience in the pharmaceutical industry, as the founder of different companies as well as an executive member of the Management Board of multinational companies.
In the recent years, he held the position of Senior Vice President for the South of Europe in Kyowa Kirin. He excels in leadership and strategic vision.
Inmaculada, who has more than 20 years experience in multinational companies in different sectors (Pharmaceutical, Banking, Technology, etc.), is responsible for Finance and Human Resources in Devon Labs.
She has led financial and HR teams with a large involvement in the creation of strategic and transformational plans contributing to a global vision of the business.
Pedro has worked for more than 30 years in various pharmaceutical companies, such as Roche, Alcalá Farma, and Kyowa Kirin.
As well as having experience in the commercial area and as a marketing director, his role in the department of Commercial Excellence at Kyowa Kirin is noteworthy.
Ana is the Director of the Medical department in Devon Labs. She has more than 30 years experience in different pharmaceutical companies, from start-ups to multinationals.
Recently, as International Medical Affairs Director in Kyowa Kirin, she worked on the development of a global medical team, designing and implementing medical plans in line with the company’s growth strategies and collaborating with multidisciplinary teams in different countries.
Miguel, Commercial director at Devon Labs, has extensive experience in the Pharmaceutical Industry.
He is noted for his commercial vision and his ability to manage teams. He was responsible for the creation of the commercial structure at Archimedes Pharma and the Rare Diseases Unit at Kyowa Kirin.